✦ LIBER ✦

Phase-I trial of intravenous continuous infusion of tumor necrosis factor in advanced metastatic carcinomas

✍ Scribed by Bertram Wiedenmann; Peter Reichardt; Ulrich Räth; Lorenz Theilmann; Birgit Schüle; Anthony D. Ho; Erich Schlick; Joachim Kempeni; Werner Hunstein; Burkhard Kommerell

Book ID: 112295095
Publisher: Springer-Verlag
Year: 1989
Tongue: English
Weight: 410 KB
Volume: 115
Category: Article
ISSN: 1432-1335
DOI: 10.1007/bf00397922

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase I trial of recombinant tumor nec

A phase I trial of recombinant tumor necrosis factor (rTNF) administered by continuous intravenous infusion in patients with disseminated malignancy

✍ Jonathan E. Schwartz; Philip Scuderi; Cyndy Wiggins; Alfred Rudolph; Evan M. Her 📂 Article 📅 1989 🏛 Springer 🌐 English ⚖ 768 KB

Phase I clinical trial of continuous inf

Phase I clinical trial of continuous infusion of tyroserleutide in patients with advanced hepatocellular carcinoma

✍ Zhen-Yu Xiao, Jin-Bin Jia, Lin Chen, Wei Zou, Xiao-Ping Chen 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 360 KB

A phase II trial of recombinant tumor ne

A phase II trial of recombinant tumor necrosis factor in patients with advanced colorectal carcinoma

✍ Nancy Kemeny; Barry Childs; William Larchian; Kim Rosado; David Kelsen 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 525 KB

A phase I trial of gemcitabine administe

A phase I trial of gemcitabine administered as a 96-h continuous intravenous infusion in patients with advanced carcinoma and lymphoma

✍ Lakshmi Rajdev; Gary Goldberg; Una Hopkins; Joseph A. Sparano 📂 Article 📅 2006 🏛 Springer US 🌐 English ⚖ 330 KB

A phase I trial of dactinomycin intraven

A phase I trial of dactinomycin intravenous infusion in patients with advanced malignancies

✍ Martin S. Blumenreich; Thomas M. Woodcock; Stephen P. Richman; Mariesa K. Jones; 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 204 KB 👁 3 views

Eighteen patients with advanced malignancies refractory to other forms of treatment were given dactinomycin (Act D) as continuous intravenous infusions. Their median age was 51 years (range, 36-67); their median performance status was 50 (range, 40-90) on the Karnofsky scale. Act D was administered

A Phase I trial of h-ras antisense oligo

A Phase I trial of h-ras antisense oligonucleotide ISIS 2503 administered as a continuous intravenous infusion in patients with advanced carcinoma

✍ C. Casey Cunningham; Jon T. Holmlund; Richard S. Geary; T. Jesse Kwoh; Andrew Do 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 84 KB 👁 2 views